Flora Growth Corp. (FLGC) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Flora Growth Corp. reported a quarterly loss of $4.93 per share, significantly worse than the Zacks Consensus Estimate of a loss of $2.13, marking an earnings surprise of -131.46% [1] - The company's revenues for the quarter ended September 2025 were $9.75 million, missing the Zacks Consensus Estimate by 22.14%, and down from $12.47 million a year ago [2] - Flora Growth shares have declined approximately 76.7% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Financial Performance - The company has not surpassed consensus EPS estimates over the last four quarters, indicating ongoing challenges in meeting market expectations [2] - The current consensus EPS estimate for the upcoming quarter is -$1.97 on revenues of $11.56 million, and for the current fiscal year, it is -$23.01 on revenues of $50.66 million [7] Market Outlook - The Zacks Rank for Flora Growth is currently 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] - The Medical - Products industry, to which Flora Growth belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may negatively impact stock performance [8]